EPAS1 and neoplasm: In addition, treatment with SAR405, but not PT2385, reduced LC3B-II expression with a corresponding increase in p62 expression in tumor tissue whereas treatment with PT2385, but not SAR405, reduced tumor tissue-expressed cyclin D1, which is encoded by CCND1, a HIF2α target gene (Choueiri and Kaelin, 2020) (Fig. EV5L), Notably, combined treatment with SAR405 and PT2385 resulted in an added effect on tumor growth inhibition (Figs. 5H and EV5J,K) and elicited a much higher rate of tumor cell apoptosis than did SAR405 or PT2385 alone (Fig. 5I).